Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling

Blood (2019) 134 (Supplement_1): 393.

https://doi.org/10.1182/blood-2019-131270

Published: 2019

Journal Articles

CD25-Dependent Feedback Control of the B-Cell Receptor and Its Oncogenic Mimics in B-Cell Malignancies

Blood (2018) 132 (Supplement 1): 776.

https://doi.org/10.1182/blood-2018-99-117553

Published: 2018

Journal Articles

Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia

Zhaohui Gu, PhD, Michelle L. Churchman, PhD, Kathryn G. Roberts, PhD, Ian Moore, MS, Xin Zhou, PhD, Joy Nakitandwe, PhD, Kohei Hagiwara, MD, Stephane Pelletier, PhD, Sebastian Gingras, PhD, Hartmut Berns, PhD, Debbie Payne-Turner, Ashley Hill, BS, Ilaria Iacobucci, PhD, Lei Shi, PhD, Stanley Pounds, PhD, Cheng Cheng, PhD, Deqing Pei, MS, Chunxu Qu, PhD, Meenakshi Devidas, PhD, Yunfeng Dai, PhD, Shalini C. Reshmi, PhD, Julie Gastier Foster, PhD, Elizabeth A. Raetz, MD, Michael J. Borowitz, MD PhD, Brent Wood, MD PhD, William L. Carroll, MD, Patrick Zweider McKay, MD PhD, Karen R. Rabin, MD PhD, Leonard A. Mattano, MD, Kelly W. Maloney, MD, Alessandro Rambaldi, MD PhD, Orietta Spinelli, PhD, Jerald Radich, MD, Mark D. Minden, MD PhD, Jacob M. Rowe, MD, Selina Luger, MD, Mark R. Litzow, MD, Martin S. Tallman, MD, Janis Recevskis, PhD, Yanming Zhang, Ravi Bhatia, MD, Jessica Kohlschmidt, PhD, Krzysztof Mrózek, MDPhD, Clara D. Bloomfield, MD, Wendy Stock, MD, Steven M. Kornblau, MD, Hagop M. Kantarjian, MD, Marina Y. Konopleva, MD PhD, William E. Evans, PharmD, Sima Jeha, MD, Ching-Hon Pui, MD, Jun J. Yang, PhD, Elisabeth M. Paietta, PhD, James R. Downing, MD, Mary V Relling, PharmD, Jinghui Zhang, Mignon L. Loh, MD, Stephen P. Hunger, MD, Charles G. Mullighan, MBBS, MD

Blood (2018) 132 (Supplement 1): 565.

https://doi.org/10.1182/blood-2018-99-111219

Published: 2018

Journal Articles

Functional and Genomic Characterization of the Interaction between Acute Lymphoblastic Leukemia Cells and the Microenvironment Identifies Pathways for Therapeutic Intervention

Hiroki Yoshihara, MDPhD, Michelle L. Churchman, PhD, Jennifer L. Peters, PhD, David B. Finkelstein, PhD, Elisabeth M. Paietta, PhD, Mark R. Litzow, MD, Charles G. Mullighan, MBBS, MD

Blood (2018) 132 (Supplement 1): 1550.

https://doi.org/10.1182/blood-2018-99-117894

Published: 2018

Journal Articles

Results of the ECOG E1900 Trial in Younger Adults with AML Using an Event Free Survival Endpoint Are Concordant with Results Based on Overall Survival: Potential for a Surrogate Endpoint to Facilitate Rapid Approval of Therapies in AML

Marlise R. Luskin, MD, Ju-Whei Lee, PhD, Hugo F. Fernandez, MD, Hillard M. Lazarus, Jacob M. Rowe, MD, Martin S. Tallman, MD, Elisabeth M. Paietta, PhD, Mark Litzow, Omar Abdel-Wahab, MD, Jay P. Patel, Ross L. Levine, MD, Zhuoxin Sun, PhD, Selina M. Luger, MD

Blood (2014) 124 (21): 2599.

https://doi.org/10.1182/blood.V124.21.2599.2599

Published: 2014

Journal Articles

Focal Adhesion Kinase Inhibitors Reverse the Stromal Adhesion Phenotype of Ikaros-Mutant B-ALL, Induce Apopotosis, and Synergize with ABL1 Tyrosine Kinase Inhibitors: A New Paradigm for Pathogenesis and Therapy of High-Risk B-ALL

Ila Joshi, PhD, Nilamani Jena, PhD, Toshimi Yoshida, PhD, Leto Paraskevopoulou, BS, Zhihong Zhang, PhD, Zhong-Ying Liu, MDPhD, Shane Korber, Daniela S. Krause, MD, Irina M. Shapiro, PhD, David T. Weaver, PhD, Jonathan A. Pachter, PhD, Elisabeth M. Paietta, PhD, Richard A. Van Etten, MDPhD, Katia Georgopoulos, PhD

Blood (2014) 124 (21): 285.

https://doi.org/10.1182/blood.V124.21.285.285

Published: 2014

Journal Articles

Hyperactive Ptpn11 Mutations Alters Leukemic Stem Cell Frequency through Mcl-1 Overexpression

Lili Chen, PhD, Wei Chen, PhD, Maria Mysliwski, Justin Serio, James Ropa, Fardokht Abulwerdi, Rebecca J. Chan, MD PhD, Jay P. Patel, Martin S. Tallman, MD, Elisabeth M. Paietta, PhD, Ari M Melnick, MD, Ross L. Levine, MD, Omar Abdel-Wahab, MD, Zaneta Nikolovska-Coleska, PhD, Andrew G. Muntean, PhD

Blood (2014) 124 (21): 3565.

https://doi.org/10.1182/blood.V124.21.3565.3565

Published: 2014

Journal Articles

Msi2 Maintains the MLL Leukemia Stem Cell Regulatory Program

Sun Mi Park, PhD, Mithat Gönen, PhD, Ly P. Vu, PhD, Gerard Minuesa, PhD, Patrick Tivnan, Trevor Barlowe, James Taggart, Yuheng Lu, Raquel P Deering, PhD, Nir Hacohen, PhD, Maria Figueroa, MD, Elisabeth M. Paietta, PhD, Martin S. Tallman, MD, Ari M. Melnick, MD, Ross L. Levine, MD, Christina Leslie, PhD, Christopher J Lengner, PhD, Michael G Kharas, PhD

Blood (2014) 124 (21): 836.

https://doi.org/10.1182/blood.V124.21.836.836

Published: 2014

Journal Articles

Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of U.S. Intergroup Trial C10403

Blood (2014) 124 (21): 796.

https://doi.org/10.1182/blood.V124.21.796.796

Published: 2014

Journal Articles

Effect of Genetic Profiling on Prediction of Therapeutic Resistance and Survival in Adult Acute Myeloid Leukemia

Roland B. Walter, MD PhD MS, Megan Othus, PhD, Elisabeth M. Paietta, PhD, Janis Racevskis, PhD, Hugo F Fernandez, MD, Ju-Whei Lee, PhD, Zhuoxin Sun, PhD, Martin S. Tallman, MD, Jay P. Patel, Mithat Gönen, PhD, Omar Abdel-Wahab, MD, Ross L Levine, MD, Elihu H. Estey, MD

Blood (2014) 124 (21): 941.

https://doi.org/10.1182/blood.V124.21.941.941

Published: 2014

Journal Articles

An Oncogene-Regulated Epigenetic Switch in T Cell Acute Lymphoblastic Leukemia

Panagiotis Ntziachristos, PhD, Aristotelis Tsirigos, Grant Welstead, Thomas Trimarchi, Linda Holmfeldt, PhD, Takashi Satoh, Elisabeth M. Paietta, PhD, Martin S. Tallman, MD, Jacob M. Rowe, MD, Giovanni Tonon, MDPhD, Jared Becksfort, MS, Laurens Kruidenier, Rab K Prinjha, Pieter Van Vlierberghe, Rudolph Jaenisch, PhD, Adolfo A. Ferrando, MD PhD, Charles G. Mullighan, MBBS, MSc, MD, Iannis Aifantis

Blood (2014) 124 (21): 56.

https://doi.org/10.1182/blood.V124.21.56.56

Published: 2014

Journal Articles

Minimal Residual Disease Assessment By Flow Cytometry in AML Is an Independant Prognostic Factor Even after Adjusting for Cytogenetic/Molecular Abnormalities

Chezi Ganzel, MD, Zhuoxin Sun, PhD, Mithat Gonen, Jay P. Patel, Omar Abdel-Wahab, MD, Hugo F Fernandez, MD, Jacob M. Rowe, MD, Martin S. Tallman, MD, Ross L. Levine, MD, Elisabeth M. Paietta, PhD

Blood (2014) 124 (21): 1016.

https://doi.org/10.1182/blood.V124.21.1016.1016

Published: 2014

Journal Articles

Cryptic Truncating Rearrangements of the Erythropoietin Receptor in Ph-like Acute Lymphoblastic Leukemia

Blood (2014) 124 (21): 128.

https://doi.org/10.1182/blood.V124.21.128.128

Published: 2014

Journal Articles

High Dose Daunorubicin Improves Survival in AML up to Age 60, Across All Cytogenetic Risk Groups Including Patients with Unfavorable Cytogenetic Risk, and FLT3-ITD Mutant AML: Updated Analyses from Eastern Cooperative Oncology Trial E1900

Marlise R. Luskin, MD, Ju-Whei Lee, PhD, Hugo F Fernandez, MD, Hillard M. Lazarus, Jacob M. Rowe, MD, Martin S. Tallman, MD, Elisabeth M. Paietta, PhD, Mark Litzow, Omar Abdel-Wahab, MD, Jay P. Patel, Ross L. Levine, MD, Zhuoxin Sun, PhD, Selina M. Luger, MD

Blood (2014) 124 (21): 373.

https://doi.org/10.1182/blood.V124.21.373.373

Published: 2014

Journal Articles

A Randomized Phase II Trial of Three Novel Regimens for Relapsed/ Refractory Acute Myeloid Leukemia (AML) Demonstrates Encouraging Results with a Flavopiridol-Based Regimen: Results of Eastern Cooperative Oncology Group (ECOG) Trial E1906

Mark R. Litzow, MD, Xin Victoria Wang, PhD, Martin P. Carroll, MD, Judith E. Karp, MD, Rhett Ketterling, MD, Scott H. Kaufmann, MD PhD, Hillard M. Lazarus, Selina M. Luger, MD, Elisabeth M. Paietta, PhD, Jacob M. Rowe, MD, Jessica K Altman, Keith W Pratz, MD, E. Randolph Broun, MD, Martin S. Tallman, MD

Blood (2014) 124 (21): 3742.

https://doi.org/10.1182/blood.V124.21.3742.3742

Published: 2014

Journal Articles

Increased Incidence of Therapy Related Myeloid Neoplasia (t-MN) After Initial Therapy for CLL with Fludarabine-Cyclophosphamide (FC) Vs Fludarabine (F): Long-Term Follow-up of US Intergroup Study E2997

Blood (2010) 116 (21): 924.

https://doi.org/10.1182/blood.V116.21.924.924

Published: 2010

Journal Articles

High Dose of Rituximab in B-Cell Malignancies.

Vladimir Hugec, MD, Doru T. Alexandrescu, MD, Yukiko Oe, MD, Elisabeth M. Paietta, PhD, Peter H. Wiernik, MD

Blood (2005) 106 (11): 5034.

https://doi.org/10.1182/blood.V106.11.5034.5034

Published: 2005

Journal Articles

Fludarabine and Cyclophosphamide Produces a Higher Complete Response Rate and More Durable Remissions than Fludarabine in Patients with Previously Untreated CLL: Intergroup Trial E2997.

Ian W. Flinn, MD, PhD, Elizabeth Kumm, MS, Michael R. Grever, MD, Donna Neuberg, ScD, Gordon W. Dewald, PhD, John M. Bennett, MD, Elisabeth M. Paietta, PhD, Mohamad A. Hussein, MD, Dennis F. Moore, Jr., MD, Martin S. Tallman, MD

Blood (2004) 104 (11): 475.

https://doi.org/10.1182/blood.V104.11.475.475

Published: 2004

NARROW

Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling

CD25-Dependent Feedback Control of the B-Cell Receptor and Its Oncogenic Mimics in B-Cell Malignancies

Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia

Functional and Genomic Characterization of the Interaction between Acute Lymphoblastic Leukemia Cells and the Microenvironment Identifies Pathways for Therapeutic Intervention

Results of the ECOG E1900 Trial in Younger Adults with AML Using an Event Free Survival Endpoint Are Concordant with Results Based on Overall Survival: Potential for a Surrogate Endpoint to Facilitate Rapid Approval of Therapies in AML

Focal Adhesion Kinase Inhibitors Reverse the Stromal Adhesion Phenotype of Ikaros-Mutant B-ALL, Induce Apopotosis, and Synergize with ABL1 Tyrosine Kinase Inhibitors: A New Paradigm for Pathogenesis and Therapy of High-Risk B-ALL

Hyperactive Ptpn11 Mutations Alters Leukemic Stem Cell Frequency through Mcl-1 Overexpression

Msi2 Maintains the MLL Leukemia Stem Cell Regulatory Program

Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of U.S. Intergroup Trial C10403

Effect of Genetic Profiling on Prediction of Therapeutic Resistance and Survival in Adult Acute Myeloid Leukemia

An Oncogene-Regulated Epigenetic Switch in T Cell Acute Lymphoblastic Leukemia

Minimal Residual Disease Assessment By Flow Cytometry in AML Is an Independant Prognostic Factor Even after Adjusting for Cytogenetic/Molecular Abnormalities

Cryptic Truncating Rearrangements of the Erythropoietin Receptor in Ph-like Acute Lymphoblastic Leukemia

High Dose Daunorubicin Improves Survival in AML up to Age 60, Across All Cytogenetic Risk Groups Including Patients with Unfavorable Cytogenetic Risk, and FLT3-ITD Mutant AML: Updated Analyses from Eastern Cooperative Oncology Trial E1900

A Randomized Phase II Trial of Three Novel Regimens for Relapsed/ Refractory Acute Myeloid Leukemia (AML) Demonstrates Encouraging Results with a Flavopiridol-Based Regimen: Results of Eastern Cooperative Oncology Group (ECOG) Trial E1906

Increased Incidence of Therapy Related Myeloid Neoplasia (t-MN) After Initial Therapy for CLL with Fludarabine-Cyclophosphamide (FC) Vs Fludarabine (F): Long-Term Follow-up of US Intergroup Study E2997

High Dose of Rituximab in B-Cell Malignancies.

Fludarabine and Cyclophosphamide Produces a Higher Complete Response Rate and More Durable Remissions than Fludarabine in Patients with Previously Untreated CLL: Intergroup Trial E2997.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only